Treatment

Long-term follow-up of direct-acting antiviral treatment of HCV infection after liver transplant shows persistent improvement in hepatic function, fibrosis, and survival rate. More

A study evaluated the early change in rates of HCV-related hospitalizations overall and HCV-related hospitalizations with hepatocellular carcinoma after expanded access to DAAs in Canada. More

Long-acting parenteral formulations of HCV treatment may allow people living with hepatitis C virus infection to be diagnosed and cured in a single encounter. More

An article gives an overview of the recommendations for the management of patients with HIV/HCV coinfection in the context of the United States. More

Early self-reported adherence to HCV treatment could be used to identify individuals who may be more likely to experience treatment failure and may benefit from additional support. More

Cutting the duration of Mavyret treatment also cut the likelihood of a cure. More

The Liver Meeting, organised by the American Association for the Study of Liver Diseases (AASLD), was held as a hybrid event from 4 to 8 November 2022. More

Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial. More

The International Liver Congress (ILC 2022), convened by the European Association for the Study of the Liver (EASL), was held in London, UK on 22-26 June 2022. More

Safety and effectiveness using 8 weeks of glecaprevir/pibrentasvir in HCV-infected treatment-naïve patients with compensated cirrhosis: The CREST study More